|
1
|
Gao ZJ, Yuan WD, Yuan JQ, Yuan K and Wang
Y: Downregulation of HIF-2α reverse the chemotherapy resistance of
lung adenocarcinoma A549 cells to cisplatin. Med Sci Monit.
24:1104–1111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen JB, Wang F, Wu JJ and Cai M:
Glutathione S-transferase pi polymorphism contributes to the
treatment outcomes of advanced non-small cell lung cancer patients
in a Chinese population. Genet Mol Res. 25:152016.
|
|
3
|
Zhang LP, Wang CP, Li LH, Tang YF and Li
WC: The interaction between smoking and CYP1A1 mspI polymorphism on
lung cancer: A meta-analysis in the Chinese population. Eur J
Cancer Care. 26:doi:10. 2017. View Article : Google Scholar
|
|
4
|
Shields PG: Molecular epidemiology of
smoking and lung cancer. Oncogene. 21:6870–6876. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu QY, Jin TB, Wang L, Zhang L, Geng T,
Liang G and Kang LL: Genetic variation in the TP63 gene is
associated with lung cancer risk in the han population. Tumour
Biol. 35:1863–1866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao L, Thakur A, Liang Y, Zhang S, Wang T,
Chen T, Meng J, Wang L, Wu F and Jin T: Polymorphisms in the TERT
gene are associated with lung cancer risk in the Chinese han
population. Eur J Cancer Prev. 23:497–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liang Y, Deng J, Xiong Y, Wang S and Xiong
W: Genetic association between ERCC5 rs17655 polymorphism and lung
cancer risk: Evidence based on a meta-analysis. Tumour Biol.
35:5613–5618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang T, Chen T, Thakur A, Liang Y, Gao L,
Zhang S, Tian Y, Jin T, Liu JJ and Chen M: Association of PSMA4
polymorphisms with lung cancer susceptibility and response to
cisplatin-based chemotherapy in a chinese han population. Clin
Transl Oncol. 17:564–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng J, Ha M, Wang Y, Sun J, Chen J, Wang
Y and Tong C: A C118T polymorphism of ERCC1 and response to
cisplatin chemotherapy in patients with late-stage non-small cell
lung cancer. J Cancer Res Clin Oncol. 138:231–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bu L, Zhang LB, Mao X and Wang P: GSTP1
Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the
clinical outcome of patients with advanced non-small cell lung
cancer. Genet Mol Res. Jun 3–2016.(Epub ahead of print). doi:
10.4238/gmr.15027611. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu D, Wu J, Shi GY, Zhou HF and Yu Y:
Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in
advanced non-small cell lung cancer. Genet Mol Res. 13:3100–3107.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang H, Gao X, Zhang X, Gong W, Peng Z,
Wang B, Wang L, Chang S, Ma P and Wang S: Glutathione S-transferase
gene polymorphisms are associated with an improved treatment
response to cisplatin-based chemotherapy in patients with non-small
cell lung cancer (NSCLC): A meta-analysis. Med Sci Monit.
24:7482–7492. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fritz A, Percy C and Jack A: International
Classification of Diseases for Oncology. 3rd edition. World Health
Organization; Geneva: 2000
|
|
14
|
Abbasi R, Ramroth H, Becher H, Dietz A,
Schmezer P and Popanda O: Laryngeal cancer risk associated with
smoking and alcohol consumption is modified by genetic
polymorphisms in ERCC5, ERCC6 and RAD23B but not by polymorphisms
in five other nucleotide excision repair genes. Int J Cancer.
125:1431–1439. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramirez JL, Rosell R, Taron M,
Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T,
Camps C and Massuti B: 14-3-3sigma methylation in pretreatment
serum circulating DNA of cisplatin-plus-gemcitabine-treated
advanced non-small-cell lung cancer patients predicts survival: The
Spanish Lung Cancer Group. J Clin Oncol. 23:9105–9112. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang Y, Thakur A, Gao L, Wang T, Zhang S,
Ren H, Meng J, Geng T, Jin T and Chen M: Correlation of CLPTM1L
polymorphisms with lung cancer susceptibility and response to
cisplatin-based chemotherapy in a chinese han population. Tumour
Biol. 35:12075–12082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Perez-Ramirez C, Canadas-Garre M, Molina
MA, Robles AI, Faus-Dader MJ and Calleja-Hernandez MA: Contribution
of genetic factors to platinum-based chemotherapy sensitivity and
prognosis of non-small cell lung cancer. Mutat Res. 771:32–58.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rulli E, Guffanti F, Caiola E, Ganzinelli
M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M and Marabese
M: The 5′UTR variant of ERCC5 fails to influence outcomes in
ovarian and lung cancer patients undergoing treatment with
platinum-based drugs. Sci Rep. 6:392172016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vrouwe MG, Pines A, Overmeer RM, Hanada K
and Mullenders LH: UV–Induced photolesions elicit
ATR-kinase-dependent signaling in non-cycling cells through
nucleotide excision repair-dependent and -independent pathways. J
Cell Sci. 124:435–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weiss JM, Weiss NS, Ulrich CM, Doherty JA
and Chen C: Nucleotide excision repair genotype and the incidence
of endometrial cancer: Effect of other risk factors on the
association. Gynecol Oncol. 103:891–896. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scharer OD: XPG: Its products and
biological roles. Adv Exp Med Biol. 637:83–92. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Na N, Dun E, Ren L and Li G: Association
between ERCC5 gene polymorphisms and breast cancer risk. Int J Clin
Exp Pathol. 8:3192–3197. 2015.PubMed/NCBI
|
|
23
|
Guo BW, Yang L, Zhao R and Hao SZ:
Association between ERCC5 gene polymorphisms and gastric cancer
risk. Genet Mol Res. 15:doi:10.4238, 2016.
|
|
24
|
Li X, Zhang J, Su C, Zhao X, Tang L and
Zhou C: The association between polymorphisms in the DNA nucleotide
excision repair genes and RRM1 gene and lung cancer risk. Thorac
Cancer. 3:239–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He C, Duan Z, Li P, Xu Q and Yuan Y: Role
of ERCC5 promoter polymorphisms in response to platinum-based
chemotherapy in patients with advanced non-small-cell lung cancer.
Anticancer Drugs. 24:300–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang D and Zhou Y: Nucleotide excision
repair gene polymorphisms and prognosis of non-small cell lung
cancer patients receiving platinum-based chemotherapy: A
meta-analysis based on 44 studies. Biomed Rep. 2:452–462. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sullivan I, Salazar J, Majem M, Pallares
C, Del Rio E, Paez D, Baiget M and Barnadas A: Pharmacogenetics of
the DNA repair pathways in advanced non-small cell lung cancer
patients treated with platinum-based chemotherapy. Cancer Lett.
353:160–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Gao G, Li X, Ren S, Li A, Xu J,
Zhang J and Zhou C: Association between single nucleotide
polymorphisms (SNPs) and toxicity of advanced non-small-cell lung
cancer patients treated with chemotherapy. PLoS One. 7:e483502012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song X, Wang S, Hong X, Li X, Zhao X, Huai
C, Chen H, Gao Z, Qian J, Wang J, et al: Single nucleotide
polymorphisms of nucleotide excision repair pathway are
significantly associated with outcomes of platinum-based
chemotherapy in lung cancer. Sci Rep. 7:117852017. View Article : Google Scholar : PubMed/NCBI
|
